Effects of cardiac rehabilitation among elderly patients with heart failure preserved ejection fraction

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN16443494

Enrollment

Registered

2023-05-30

Start date

2023-06-01

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Effects of cardiac rehabilitation (CR) on elderly patients with chronic heart failure (CHF) Circulatory System

Interventions

Participants will enter a prospective cohort study researching cardiac rehabilitation training. The training length is divided into 3 stages in total, the first stage is 4 weeks, the second stage is 1

Eligibility

Sex/Gender

All

Age

65 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for heart failure with preserved ejection fraction (HFpEF) 2. Age =65 to 80 years old 3. Meet the indications for cardiac rehabilitation

Exclusion criteria

Exclusion criteria: 1. Aged<65 years old 2. Does not meet the indications for cardiac rehabilitation 3. Contraindications to cardiac rehabilitation

Design outcomes

Primary

Measure	Time frame
Current primary outcomes as of 21/05/2026: 1. Exercise endurance measured using the 6-minute walk test at baseline, and 6-week post-intervention 2. Cardiorespiratory function: peak oxygen uptake (peakVO2) and anaerobic threshold (AT) measured using the Cardiorespiratory Exercise Test (CPET), and the Cortex META CONTROL 3000 system at baseline, and 6-week post-intervention Previous primary outcomes: Exercise endurance measured using the 6-minute walk test at 6 months (study finish)	—

Measure

Time frame

Current primary outcomes as of 21/05/2026: 1. Exercise endurance measured using the 6-minute walk test at baseline, and 6-week post-intervention 2. Cardiorespiratory function: peak oxygen uptake (peakVO2) and anaerobic threshold (AT) measured using the Cardiorespiratory Exercise Test (CPET), and the Cortex META CONTROL 3000 system at baseline, and 6-week post-intervention Previous primary outcomes: Exercise endurance measured using the 6-minute walk test at 6 months (study finish)

—

Secondary

Measure	Time frame
Current key secondary outcome: 1. Physical Function Performance: balance, gait and chair-stand tests, measured using the Short-Time Physical Fitness Scale (SPPB) at baseline, and 6-week post-intervention 2. Quality of Life: physical and emotional dimension scoring and total score, measured using the Minnesota Heart Failure Quality of Life Questionnaire (MLHFQ) at baseline, and 6 weeks after intervention Previous key secondary outcome: 1. Peak VO2 measured using cardiopulmonary exercise testing (CPET) at 6 months (study finish) 2. B-type natriuretic peptide (BNP) measured using biochemical testing equipment and standard techniques at 6 months (study finish)	—

Measure

Time frame

Current key secondary outcome: 1. Physical Function Performance: balance, gait and chair-stand tests, measured using the Short-Time Physical Fitness Scale (SPPB) at baseline, and 6-week post-intervention 2. Quality of Life: physical and emotional dimension scoring and total score, measured using the Minnesota Heart Failure Quality of Life Questionnaire (MLHFQ) at baseline, and 6 weeks after intervention Previous key secondary outcome: 1. Peak VO2 measured using cardiopulmonary exercise testing (CPET) at 6 months (study finish) 2. B-type natriuretic peptide (BNP) measured using biochemical testing equipment and standard techniques at 6 months (study finish)

—

Countries

China

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Jun 11, 2026